Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
Lescure FX, et al.〔【Lancet Respir Med. 2021 Mar 4:S2213-2600(21)00099-0〕（査読済み）
Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19